Artal Group S.A. Blueprint Medicines Corp Transaction History

Artal Group S.A.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$94.25 - $115.99 $9.43 Million - $11.6 Million	-100,000 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $8.28 Million - $10.1 Million	100,000 New	100,000 $8.8 Million
Q3 2020 Nov 13, 2020	SELL	$66.45 - $92.7 $36.5 Million - $51 Million	-550,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $8.56 Million - $11.9 Million	150,000 Added 37.5%	550,000 $42.9 Million
Q4 2019 Feb 13, 2020	SELL	$66.73 - $82.59 $13.3 Million - $16.5 Million	-200,000 Reduced 33.33%	400,000 $32 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $10.9 Million - $15.2 Million	-150,000 Reduced 20.0%	600,000 $44.1 Million
Q2 2019 Aug 09, 2019	SELL	$73.54 - $97.8 $7.35 Million - $9.78 Million	-100,000 Reduced 11.76%	750,000 $70.7 Million
Q1 2019 May 10, 2019	BUY	$48.7 - $86.6 $12.2 Million - $21.7 Million	250,000 Added 41.67%	850,000 $68 Million
Q4 2018 Feb 11, 2019	BUY	$45.57 - $74.26 $4.56 Million - $7.43 Million	100,000 Added 20.0%	600,000 $32.3 Million
Q3 2018 Nov 09, 2018	SELL	$58.91 - $78.32 $11.8 Million - $15.7 Million	-200,000 Reduced 28.57%	500,000 $39 Million
Q2 2018 Aug 10, 2018	BUY	$60.96 - $101.18 $15.2 Million - $25.3 Million	250,000 Added 55.56%	700,000 $44.4 Million
Q1 2018 May 10, 2018	BUY	$73.28 - $102.95 $25.6 Million - $36 Million	350,000 Added 350.0%	450,000 $41.3 Million
Q4 2017 Feb 09, 2018	BUY	$62.91 - $88.32 $6.29 Million - $8.83 Million	100,000	100,000 $7.54 Million

352

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.76B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.